X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (mannitol).
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: N/AProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aptar Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 04, 2022
Details:
PXS‐5505 has progressed to a phase 2 clinical trial looking for evidence of disease modifying effects in the bone cancer myelofibrosis as a monotherapy so exploring its additional potential to address cancers where fibrosis is limiting the clinical benefit of chemotherapy.
Lead Product(s): PXS-5505,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: PXS-5505
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Rochester
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
The phase 1 trial of the drug known as PXS-6302 tested 4 different strengths formulated as an easy to apply cream in 4 subjects as a single dose, scaling to the highest dose applied daily for 7 days in a further 6 subjects.
Lead Product(s): PXS-6302
Therapeutic Area: Dermatology Product Name: PXS-6302
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
As per agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device & further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.
Lead Product(s): Mannitol API
Therapeutic Area: Genetic Disease Product Name: Bronchitol
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aptar Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 17, 2021
Details:
PXS‐5505 is currently progressing well through a phase 1c/2 clinical trial looking for evidence of disease modifying effects in bone cancer myelofibrosis as a monotherapy.
Lead Product(s): PXS-5505
Therapeutic Area: Oncology Product Name: PXS-5505
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
The phase 1c/2a trial MF‐101 aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Lead Product(s): PXS-5505
Therapeutic Area: Oncology Product Name: PXS-5505
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Parexel Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2021
Details:
Together Australian pharmaceutical and University of Western Australia will test Pharmaxis’s topical discovery, known as PXS-6302, which has shown promising pre-clinical results in restraining the enzymes that play a significant role in the development of scar tissue.
Lead Product(s): PXS-6302
Therapeutic Area: Dermatology Product Name: PXS-6302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
